DBEU - ETF AI Analysis

Top Page

Xtrackers MSCI Europe Hedged Equity ETF (DBEU)

Rating:64Neutral

Price Target:$57.00▲(5.59% Upside)

DBEU, the Xtrackers MSCI Europe Hedged Equity ETF, earns a solid overall rating thanks to its sizable positions in financially strong companies like Novartis, HSBC, and AstraZeneca, which benefit from robust profitability, positive earnings sentiment, and generally supportive technical trends. The fund also holds quality names such as ASML and Siemens, though pockets of valuation risk and mixed or bearish technical signals in some holdings like ASML and SAP, along with sector and regional concentration in European equities, slightly temper its appeal.

Positive Factors

Strong Year-to-Date PerformanceThe ETF has delivered strong gains so far this year, showing solid overall momentum.

Leading European Blue-Chip HoldingsTop positions like ASML, Shell, Roche, HSBC, Novartis, and Nestlé have mostly shown strong or steady performance, helping support the fund’s returns.

Broad European Country DiversificationExposure across major European markets such as the UK, Germany, France, Switzerland, Spain, Sweden, and Italy helps reduce the impact of weakness in any single country.

Negative Factors

Recent Short-Term WeaknessThe ETF has shown weak performance over the last month and three months, which may signal near-term volatility or a pause in its upward trend.

Moderate Expense RatioThe fund’s fees are not especially low, so costs may eat into returns more than with some cheaper index ETFs.

Concentration in a Few Large HoldingsA small group of stocks, including ASML and several large European companies, make up a meaningful portion of the portfolio, increasing the impact if any of them perform poorly.

DBEU vs. SPDR S&P 500 ETF (SPY)

AUM: 787.99M
Region: Europe
Expense Ratio: 0.46%
Beta: 0.61
Issuer: Xtrackers
Inception Date: Oct 01, 2013
Dividend Yield: 4.05%
Asset Class: Equity
Index Tracked: MSCI Europe 100% Hedged to USD Net Variant

DBEU Summary

DBEU is an ETF that follows the MSCI Europe U.S. Dollar Hedged Index, giving you broad exposure to major European companies while trying to reduce the impact of currency swings between the euro and the U.S. dollar. It holds well-known names like Nestlé, Shell, HSBC, and Novartis, across many sectors including finance, health care, and consumer goods. Someone might invest in DBEU to diversify beyond the U.S. and tap into Europe’s long-term growth, without worrying as much about exchange rates. A key risk is that European stock prices can still go up and down with the overall market.

How much will it cost me?

This ETF has an expense ratio of 0.46%, which means you’ll pay about $4.60 per year for every $1,000 invested. That’s a bit higher than the average low-cost index ETF because this fund is passively managed but includes a currency hedging strategy, which adds to its costs.

What would affect this ETF?

DBEU could benefit if Europe’s economy strengthens, boosting large companies like ASML, Nestlé, and major banks, while its currency hedging helps protect U.S. investors from swings between the euro and the dollar. On the other hand, slower European growth, financial sector stress, energy price shocks, or new regulations affecting big banks, drug makers, or industrial firms like Siemens and SAP could weigh on the ETF’s future performance.

DBEU Top 10 Holdings

DBEU leans heavily on Europe’s corporate heavyweights, with ASML acting as the main engine: its strong year-to-date run has been a key performance driver despite some recent wobbling. Health care names like Roche and Novartis are steadily pulling their weight, giving the fund a defensive backbone, while consumer giant Nestlé has been more mixed, occasionally losing steam. Financials such as HSBC and Allianz add income and stability but haven’t been clear leaders lately. Overall, it’s a developed Europe story, spread across sectors but with notable strength in pharma and industrial tech.

DBEU top ten holdings
Name	Company Name	Weight %	Market Value	Market Cap	Yearly Gain	Overall Rating
NL:ASML	ASML Holding NV	4.65%	$36.28M	EUR 539.67B	50.70%	76Outperform
RHHVF	Roche Holding AG	―	―	―	―	73Outperform
GB:SHEL	Shell (UK)	2.23%	$17.39M	GBP 229.30B	40.01%	73Outperform
GB:HSBA	HSBC Holdings	2.12%	$16.51M	GBP 218.81B	19.37%	80Outperform
CH:NOVN	Novartis AG	2.09%	$16.33M	CHF 244.89B	35.30%	80Outperform
CH:NESN	Nestlé SA	1.84%	$14.37M	CHF 217.87B	9.36%	71Outperform
AZN	AstraZeneca	―	―	―	―	80Outperform
DE:SAP	SAP SE	1.69%	$13.15M	EUR 246.65B	-6.46%	66Neutral
DE:SIE	Siemens	1.58%	$12.29M	EUR 202.50B	7.55%	74Outperform
DE:ALV	Allianz	1.33%	$10.34M	EUR 166.13B	23.20%	67Neutral

DBEU Technical Analysis

Technical Analysis SentimentPositive

Last Price53.98

Price Trends

50DMA53.92Positive

100DMA53.94Positive

200DMA52.10Positive

Market Momentum

MACD0.07Negative

RSI52.93Neutral

STOCH83.95Negative

Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For DBEU, the sentiment is Positive. The current price of 53.98 is above the 20-day moving average (MA) of 53.58, above the 50-day MA of 53.92, and above the 200-day MA of 52.10, indicating a bullish trend. The MACD of 0.07 indicates Negative momentum. The RSI at 52.93 is Neutral, neither overbought nor oversold. The STOCH value of 83.95 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DBEU.

DBEU Peer Comparison

Comparison Results

DBEU against its peer funds
Name	Price	Price Target	AUM	Expense Ratio	Overall Rating
DBEU	$53.98	$57.00(5.59% Upside)	$787.99M	0.46%	64Neutral
VGK	$87.54	$104.35(19.21% Upside)	$29.73B	0.06%	61Neutral
IEUR	$74.40	$88.41(18.83% Upside)	$9.55B	0.09%	63Neutral
EZU	$65.16	$80.47(23.50% Upside)	$9.25B	0.50%	63Neutral
SPEU	$53.98	$63.86(18.30% Upside)	$706.97M	0.07%	62Neutral
GSEU	$48.09	$58.43(21.51% Upside)	$171.00M	0.25%	62Neutral

Performance Comparison

DBEU and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DBEU	Xtrackers MSCI Europe Hedged Equity ETF	53.98	7.51	16.15%
VGK	Vanguard FTSE Europe ETF	87.54	9.75	12.53%
IEUR	iShares Core MSCI Europe ETF	74.40	8.18	12.36%
EZU	iShares MSCI Eurozone ETF	65.16	4.69	7.75%
SPEU	SPDR Portfolio Europe ETF	53.98	5.80	12.03%
GSEU	Goldman Sachs ActiveBeta Europe Equity ETF	48.09	5.68	13.38%

Glossary

BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.